I’m pleased to share a biography that reflects my journey as a global pharmaceutical and biotechnology executive across medical affairs, clinical development, regulatory strategy, and commercialization. Over the past three decades, I’ve had the opportunity to lead across respiratory, rare disease, oncology, endocrinology, infectious disease, and global market expansion while building teams, advancing innovation, and supporting product launches worldwide. Here is my biography.

I'm a global medical affairs leader with over two decades of experience spanning clinical research, regulatory strategy, and pharmaceutical innovation across Latin America and the United States. Throughout my career, I've had the privilege of guiding high-performing teams, launching impactful therapies, and aligning regional execution with global vision—most recently as Head of Medical Affairs for Emerging Therapy Areas at Novo Nordisk. Passionate about advancing patient outcomes and fostering collaborative leadership, I bring a strategic, people-centered approach to everything I do in the healthcare space.

Dr. Michael E. Kuligowski, MD, PhD, MBA, is a globally recognized physician-executive with over four decades of leadership in dermatology, clinical development, and pharmaceutical strategy. With a distinguished career spanning Europe and the United States, he has led the development and approval of numerous dermatologic therapies, including Opzelura® for atopic dermatitis and vitiligo. Known for his scientific rigor, strategic foresight, and collaborative leadership, Dr. Kuligowski continues to influence the future of dermatologic innovation through executive roles, advisory board appointments, and pro-bono consulting in the life sciences sector.

Matthew Smollin, PharmD, is an accomplished leader in medical affairs and clinical innovation with over 15 years of clinical experience and a decade of industry expertise spanning clinical research, regulatory strategy, and team leadership. As Vice President of Medical Affairs at Karius, Inc., he directs medical and scientific strategies, guiding breakthrough advancements in molecular diagnostics while navigating complex FDA and Medicare regulatory processes. Throughout his career, he has successfully built and managed high-performing teams, fostered strong relationships with key opinion leaders, and played a pivotal role in clinical trial design, publication strategy, and scientific engagement. A respected speaker and thought leader, Dr. Smollin’s expertise in infectious disease diagnostics and next-generation sequencing has shaped industry best practices and advanced clinical innovation. His dedication to scientific excellence, strategic vision, and ability to translate complex medical insights into impactful solutions make him a driving force in the evolution of precision medicine and diagnostic technologies.